Neurofibromatosis type 1 (NF1), a common inherited disorder, causes skin-pigmentation and CNS abnormalities, and increases the risk of developing several types of cancer. It varies widely in clinical presentation, even in family members carrying an identical mutation at the NF1 locus, suggesting genetic or environmental modifiers. To probe underlying mechanisms, Shin, Padmanabhan et al. studied the zebrafish homologues of human NF1 – nf1a and nf1b – and used targeted approaches to create nf1-null zebrafish, which showed melanophore defects and a range of CNS abnormalities at the larval stage. As hypothesised for human NF1, zebrafish nf1 genes also act as tumour suppressors: nf1-null larvae showed hyperactivation of Ras in the spinal cord, and combined loss of nf1 and p53 accelerated tumorigenesis. These data indicate that zebrafish nf1a and nf1b are tumour suppressors with crucial roles in CNS development. This is also the first animal model of NF1 in which pigmentation defects – an important feature of the human disease – have been documented. Page 881
Zebrafish model of neurofibromatosis type 1
Zebrafish model of neurofibromatosis type 1. Dis Model Mech 1 November 2012; 5 (6): 707. doi:
Download citation file:
Advertisement
Cited by
DMM Journal Meeting 2024: Pre-clinical Modelling of Human Genetic Disease and Therapy

Registration is now open for our 2024 Journal Meeting. Rapid advances in gene editing and genetic technologies have revolutionised our ability to model human genetic disease and provided new hope for gene therapies. At this Meeting, we will present the very latest advances in modelling human genetic disease.
Moving towards heart success – Disease Models & Mechanisms Special Issue

DMM's most recent special issue compiles articles that aim to move heart failure to heart success by fundamentally addressing the roots of failure to identify curative strategies.
Crossroads in Virology

Our October Editorial written by Sumana Sanyal emphasises the urgency of a concerted effort in understanding virus–host interactions to inform the development of therapeutics and vaccines, helping to predict disease outcomes. Read the full Editorial here.
A Model for Life - an interview with Professor Kiran Musunuru




Read our new A Model for Life interview with Kiran Musunuru. Prof Musunuru investigates the mechanisms of disease in model systems, with the ultimate goal of developing innovative gene editing therapies.
Sustainable Conferencing Initiative

Through our Sustainable Conferencing Grants, we promote the use of new technology and greener modes of travel. Our blog posts showcase examples of sustainability in action and share experience about how new technologies and conference formats work in practice.
Other journals from
The Company of Biologists